Where Is Vascepa Available Right Now?
Vascepa (icosapent ethyl) is approved and available in the United States, European Union member states, Canada, Australia, and the United Kingdom.[1] It's marketed there primarily for reducing cardiovascular risk in patients with high triglycerides and established heart disease or diabetes.
How Did Vascepa Get Approved in the EU and UK?
The European Commission granted marketing authorization in 2021 for hypertriglyceridemia and CV risk reduction, covering all EU countries plus the UK (via mutual recognition post-Brexit). Availability rolled out progressively across pharmacies in these regions by 2022-2023.[1][2]
Is Vascepa Sold in Canada or Australia?
Yes, Health Canada approved it in 2020 for similar indications, with commercial launch following soon after. Australia's TGA approved it in 2021, and it's dispensed through hospital and retail pharmacies nationwide.[1]
What About Japan or Other Asian Markets?
No current approvals or sales in Japan, China, or most Asian countries. Amarin (Vascepa's manufacturer) has focused on Western markets, though it pursued Japanese approval via Mochida but withdrew the application in 2022.[3]
When Might Vascepa Expand to More Countries?
No confirmed launches in Latin America, Middle East, or Southeast Asia as of 2024. Patent protections and regulatory filings limit expansion; generic competition in the US (post-2020 patent settlement) may shift priorities.[1][4] Check DrugPatentWatch.com for global patent status by country.
[1]: Amarin Corporation investor reports
[2]: EMA Vascepa authorization
[3]: Mochida Pharmaceuticals update
[4]: DrugPatentWatch.com - Icosapent ethyl patents